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Summary 
The porphyrias arise from predominantly inherited catalytic deficiencies of specific enzymes in heme biosynthesis. All 
genes encoding these enzymes have been cloned and several mutations underlying the different types of porphyrias 
have been reported. Traditionally, the diagnosis of porphyria is made on the basis of clinical symptoms, characteristic 
biochemical findings, and specific enzyme assays. In some cases however, these diagnostic tools reveal overlapping 
findings, indicating the existence of dual porphyrias with two enzymes of heme biosynthesis being deficient simultane-
ously. Recently, it was reported that the so-called Chester porphyria shows features of both variegate porphyria and 
acute intermittent porphyria. Linkage analysis revealed a novel chromosomal locus on chromosome 11 for the underly-
ing genetic defect in this disease, suggesting that a gene that does not encode one of the enzymes of heme biosynthesis 
might be involved in the pathogenesis of the porphyrias. After excluding candidate genes within the linkage interval, we 
identified a nonsense mutation in the porphobilinogen deaminase gene on chromosome 11q23.3, which harbors the 
mutations causing acute intermittent porphyria, as the underlying genetic defect in Chester porphyria. However, we 
could not detect a mutation in the coding or the promotor region of the protoporphyrinogen oxidase gene that is mutated 
in variegate porphyria. Our results indicate that Chester porphyria is neither a dual porphyria, nor a separate type of 
porphyria, but rather a variant of acute intermittent porphyria. Further, our findings largely exclude the possibility that a 
hitherto unknown gene is involved in the pathogenesis of the porphyrias. 
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Introduction 
 
 The porphyrias are a group of rare metabolic 
diseases which arise from an either inherited or acquired 
dysfunction of one of the eight enzymes involved in heme 
biosynthesis. Disturbance of any of these enzymes leads 
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to an accumulation of the preceding metabolites with a 
measurable increase of porphyrins and/or porphyrin pre-
cursors (Kauppinen 2005). 
 According to the major site of expression of the 
particular enzymatic deficiency, the porphyrias can be 
classified into erythropoietic and hepatic forms. From a 
clinical point of view however, it seems more suitable to 
classify the porphyrias in acute and non-acute forms, 
thereby primarily considering whether the patient does or 
does not experience acute neurovisceral attacks (Lip et al. 
1993). These acute porphyric attacks are life-threatening 
events and can present with such heterogeneous symp-
toms as colicky abdominal pain, vomiting, electrolyte 
dysregulation (hyponatremia), constipation, tachycardia, 
hypertension, muscle pain and weakness, seizures, paresis 
of the upper and lower extremities, paralysis, and a vari-
ety of often confusing neurological and psychiatric 
symptoms (Crimlisk 1997).  
 The acute porphyrias are comprised of acute 
intermittent porphyria (AIP), variegate porphyria (VP), 
hereditary coproporphyria (HCP), and δ-aminolevulinic 
acid dehydratase (ALA-D) deficiency porphyria (Frank 
and Christiano 1998). Whereas AIP is the most frequent 
type of porphyria worldwide, in some countries other 
acute forms might be predominant, as is the case for VP 
in South Africa and in Chile (Groenewald et al. 1998, 
Frank et al. 2001). Beside the aforementioned neurovis-
ceral attacks, individuals suffering from VP or HCP can 
present with cutaneous symptoms, including increased 
photosensitivity, abnormal skin fragility, blisters on sun-
exposed areas, erosions, chronic scarring, and post-
imflammatory hyperpigmentation. By contrast, however, 
AIP and ALA-D deficiency porphyria do not present with 
cutaneous symptoms (Kauppinen 2005). 
 Diagnose in an acute porphyria traditionally 
involves three major steps. First, the medical history 
including the frequency of acute attacks, the family his-
tory, and a thorough physical examination. Second, 
biochemical measurement of porphyrins and porphyrin 
precursors in urine and feces. Third, determination of 
specific enzymatic activities in lymphocytes or fibro-
blasts which is usually only possible in specialized 
laboratories. But even when using all these diagnostic 
tools, the results might still be confusing (Da Silva et al. 
1995, Grandchamp et al. 1996). This is particularly true 
for the so-called dual porphyrias. 
 In families with dual porphyrias, simultaneous 
defeciency of two enzymes along the heme biosynthetic 
pathway are detected. Single cases have been described 
but, overall, seem to be extremely rare (Watson et al. 
1975, Levine et al. 1978, Day et al. 1982, Doss 1988, 
Doss 1989a, Doss 1989b, Sturrock et al. 1989, Nordmann 
et al. 1990, Gregor et al. 1994, Sieg et al. 1995, Freese-
mann et al. 1997, Doss et al. 2002).  
 In 1985, a new form of porphyria with auto-
somal dominant inheritance, designated Chester 
porphyria (CP), was described in a large kindred from the 
United Kingdom. Affected family members presented 
with acute porphyric attacks and revealed biochemical 
characteristics of both VP and AIP, with some patients 
showing intermediate patterns. Measurement of enzy-
matic acitivities demonstrated reduced activity of 
porphobilinogen deaminase (PBGD) and protoporphy-
rinogen oxidase (PPOX) in affected individuals (McColl 
et al. 1985). In 1992, the results of a genome wide link-
age analysis performed in the CP family suggested that a 
novel gene residing on chromosome 11q might be in-
volved in the pathogenesis of this subtype of dual 
porphyria (Norton et al. 1993). Interestingly, this locus 
did not contain any of the genes encoding enzymes cata-
lyzing major steps in heme biosynthesis. 
 In an effort to define the molecular basis of this 
novel porphyria we cloned and screened two candidate 
genes, SDHD and FDX1, on chromosome 11q, which we 
considered good candidates for CP. However, direct 
sequencing analysis of these genes did not reveal any 
mutation underlying CP.  
 Although the original linkage report from Nor-
ton and coworkers excluded the PBGD and PPOX gene 
as candidates (Norton et al. 1993), we nevertheless se-
quenced these genes because the biochemical and 
enzymatic data indicated deficiencies of the encoded 
enzymes. Sequencing analysis of the coding regions of 
the PPOX gene and its promoter region revealed no muta-
tions. In exon 9 of the PBGD gene, however, we detected 
a nonsense mutation, designated R149X, in all affected 
individuals studied.  
 Although proposed by previous biochemical and 
enzymatic studies, we herein excluded on the basis of 
molecular genetic analyses the existence of a novel type 
of autosomal dominant porphyria resulting in a dual en-
zyme deficiency.  
 
Methods 
 
Samples and DNA extraction 
 A detailed pedigree of the extensive CP family 
was previously published elsewhere (Norton et al. 1993). 
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Here, we studied DNA samples of ten individuals from 
this family. Five of them had been classified as affected 
and the other five as unaffected, based on the broad clini-
cal, biochemical, and enzymatic studies previously 
performed (McColl et al. 1985, Qadiri et al. 1986). Addi-
tionally, 100 healthy, unrelated Caucasian control 
individuals were included in this study. All individuals 
provided informed consent for inclusion in the study 
according to guidelines set forth by the local institutional 
review board. Genomic DNA was isolated according to 
standard techniques (Sambrook et al. 1991). 
 
PCR amplification and mutation screening 
 A mutation detection strategy for the PBGD and 
PPOX gene was developed based on PCR amplification 
of all PBGD and PPOX exons and their adjacent splice 
sites using PCR primers and conditions that were either 
published recently as is the case for PPOX [6] or specifi-
cally designed for this study using the primer design 
program Oligo 4 (Molecular Biology Insights, Inc., Cas-
cade, CO 80809-1333) as is the case for PBGD. For 
amplification of exon 9 of the PBGD gene in this study, 
the following primers were used: 
 
PBGD exon 9F: 5’-GGAAAGACAGACTCAGGCAG-3’ 
PBGD exon 9R: 5’-GAAAGGAGATGCAGATGAGC-3’. 
 
 PCR was carried out according to the following 
program: initial denaturation at 95 °C for 5 minutes, fol-
lowed by 35 cycles of denaturation at 95 °C for 45 
seconds, annealing at primer specific temperatures as 
outlined in Table 1 for 1 minute, and extension at 72 °C 
for 1 minute and 15 seconds, followed by a final exten-
sion at 72 °C for 10 minutes, in a Biometra® TGradient 
thermal cycler (Whatman Biometra®, Göttingen, Ger-
many). Each amplification reaction contained ~100 ng of 
genomic DNA, 50 ng/µl of each forward and reverse 
primer and 35 µl of Platinum Taq® PCR Super Mix (Invi-
trogen® Life Technologies, Karlsruhe, Germany), in a 
total volume of 38 µl. 
 PCR products were purified in a first step, using 
the High Pure PCR product purification kit (Roche, 
Basel, Switzerland). In a second step, PCR fragments 
were purified on Edge Centriflex columns (Edge BioSys-
tems, Gaithersburg, MD) and sequenced directly with 
POP-6 polymer using an ABI Prism 310 Genetic Ana-
lyzer from Applied Biosystems Inc. (Applied Biosystems, 
Foster City, CA). 
Screening of the SDHD and FDX1 gene as candidates 
 Upon screening the OMIM genome database, we 
detected several genes in the vicinity of the Chester por-
phyria locus on chromosome 11q, two of which, SDHD 
and FDX1, we considered as good candidates. From both 
genes human cDNA sequences were available (accession 
numbers NM_003002 and XM_016467, respectively) 
and, subsequently, we screened available genomic data-
bases, cloned these genes in silico and established their 
exon-intron-boundaries using methods previously de-
scribed in detail (Frank et al. 2001). Primer pairs to 
amplify coding regions and adjacent splice sites of both 
genes were generated using the primer design program 
Oligo 4 (Molecular Biology Insights, Inc., Cascade, CO 
80809-1333). DNA from affected and unaffected indi-
viduals of the CP family was PCR amplified and 
screened for mutations as aforementioned for the PBGD 
and PPOX gene. 
 
Results 
 
Exclusion of the SDHD and FDX1 gene as candidates 
 Both the SDHD and FDX1 gene consist of 4 
exons, respectively. Automated sequencing analysis of all 
exons and adjacent splice sites in both genes did not re-
veal any mutation in the ten individuals from the CP 
family (data not shown). 
 
Mutation screening in the PPOX gene 
 In all members of the CP family, automated 
sequencing of the entire coding regions, adjacent splice 
sites and the promoter region of the PPOX gene did not 
reveal any sequence varaiation suggestive of a mutation 
(data not shown). 
 
Mutation detection and verification in the PBGD gene 
 Amplification of exon 9 of the PBGD gene re-
sulted in a PCR product 209 bp in size, containing 63 bp 
of intron 8, 76 bp of exon 9, and 70 bp of intron 9. Auto-
mated sequence analysis of this PCR product revealed a 
sequence variation in four of the five CP family members 
previously classified as being affected. The mutation 
consisted of a C-to-T transition at nucleotide position 445 
of the PBGD cDNA, numbered according to GenBank 
accession number NM_000190, counting the first base of 
the initiating methionine as number 1 (Figure 1). This 
base substitution leads to a nonsense mutation, consisting 
of an amino acid conversion from arginine to a premature 
termination codon at position 149 in the deduced amino 
acid sequence, designated R149X.  
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 Since the mutation did not introduce a restriction 
site for a restriction endonuclease we used automated 
sequencing of newly synthesized PCR products to verify 
the sequence variation detected in exon 9 of the PBGD 
gene. Hereby, we confirmed the absence of this nucleo-
tide deviation in 200 chromosomes from unaffected, 
unrelated Caucasian control individuals and excluded it 
as a common polymorphism (data not shown). 
 
 
exon 9 
wild-type allele 
 
exon 9 
R149X mutant allele 
 
Fig. 1. Results of mutation analysis in the Chester porphyria 
family. Nonsense mutation R149X in exon 9 of the PBGD gene, 
consisting of a heterozygous C-to-T transition (lower panel), 
indicated by an arrow. 
 
 
Discussion 
 
 In this study we sought to define the molecular 
basis of CP by screening two putative candidate genes, 
SDHD and FDX1, as well as the PPOX and PBGD genes 
for mutations underlying this unique disorder. 
 The first report of the CP family was published 
in 1985. McColl and coworkers described a large family 
residing in Chester, England, that revealed typical acute 
porphyric attacks and the biochemical features of both 
VP and AIP, with some family members even demon-
strating overlapping values of porphyrins and porphyrin 
precursors in the urine and feces. Interestingly, confirma-
tion of these biochemical data by enzyme assays 
performed on peripheral blood mononuclear cells showed 
decreased activities of PBGD in some affected individu-
als while other family members also revealed decreased 
activities of PPOX. Thus, the authors concluded that 
affected family members were suffering from a novel 
type of one of the so called dual porphyrias in which the 
simultaneous dysfunction of two enzymes of heme bio-
synthesis is proposed (McColl et al. 1985). 
 In general, the occurrence of dual porphyrias 
seems to be extremely rare and only occasionally single 
cases with no obvious Mendelian transmission in affected 
individuals and families have been reported to date (Wat-
son et al. 1975, Levine et al. 1978, Day et al. 1982, Doss 
1988, Doss 1989a, Doss 1989b, Sturrock et al. 1989, 
Nordmann et al. 1990, Gregor et al. 1994, Sieg et al. 
1995, Freesemann et al. 1997, Doss et al. 2002). The 
majority of theses cases comprise a combination of por-
phyria cutanea tarda (PCT) with one of the dominantly 
inherited acute porphyrias (AIP, VP, or HCP) [Watson et 
al. 1975, Levine et al. 1978, Day et al. 1982, Doss 1988, 
Doss 1989a, Doss 1989b, Sturrock et al. 1989, Sieg et al. 
1995, Freesemann et al. 1997, Doss et al. 2002). PCT is 
the most frequent type of porphyria worldwide and, fur-
ther, represents the only porphyria variant that is not 
exclusively hereditary since a sporadic occurrence (type I 
or acquired PCT) as well as an autosomal dominant 
transmission of the disease (type II or inherited PCT) 
have been reported, with some authors even proposing 
the existence of a third subtype of PCT (type III PCT) 
(Elder 1998). In two case reports, a simultaneous occur-
rence of the acute porphyria HCP with either AIP or the 
autosomal recessive disorder congenital erythropoietic 
porphyria (CEP) have been described (Nordmann et al. 
1990, Gregor et al. 1994).  
 In all aforementioned reports, the diagnosis of a 
dual porphyria was established on the basis of clinical 
symptoms, biochemical measurement of porphyrins 
and/or porphyrin precursors, and enzymatic assays (Wat-
son et al. 1975, Levine et al. 1978, Day et al. 1982, Doss 
1988, Doss 1989a, Doss 1989b, Sturrock et al. 1989, 
Nordmann et al. 1990, Gregor et al. 1994, Sieg et al. 
1995, Freesemann et al. 1997, Doss et al. 2002). Surpris-
ingly, however, in none of these patients and families the 
diagnosis of a double porphyria could be confirmed on 
the molecular genetic level by demonstrating the simulta-
neous occurrence of disease causing mutations in those 
individuals obviously affected by a combined deficiency 
of two enzymes of heme biosynthesis. In the majority of 
these cases this might possibly be due to the fact that the 
frequency of type I PCT is much higher than that of type 
II PCT. Taking this into consideration, it is understand-
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able that there has been no report about a patient with 
mutations in two genes encoding enzymes of heme bio-
synthesis thus far.  
 Since the co-existence of both VP and AIP had 
not been previously reported it was tempting for McColl 
and colleagues to propose a new type of porphyria at that 
time (McColl et al. 1985). Consistent with that notion, 
Norton and coworkers performed a genome wide linkage 
analysis in search of a candidate locus for a putative gene 
harboring mutations contributing to the unique biochemi-
cal and enzymatic expression pattern observed in affected 
individuals from the CP family, in which the disease 
segregated in an autosomal dominant fashion. The results 
of their approach indicated linkage of CP to a locus on 
chromosome 11q23.1 within an interval of approximately 
1 Mb, thereby excluding both the PPOX and the PBGD 
gene as candidates since they reside on chromosomes 
1q22-23 and 11q23.3, respectively. Although the PBGD 
gene on 11q23.3 was in close proximity to the candidate 
locus, the authors excluded this gene as a candidate on 
the basis of several recombination events encountered in 
members of the CP family (Norton et al. 1993). Thus, 
their results indeed indicated the existence of a hitherto 
unknown gene defect causing CP. 
 Searching genomic databases, we detected two 
genes, FDX1 and SDHD, residing on chromosome 11q22 
and 11q23.1, respectively, which we considered good 
candidates for CP. Thus, we subsequently cloned these 
genes in silico, established their exon-intron-boundaries 
using methods previously described in detail (Frank et al. 
2001), and screened both genes for disease causing muta-
tions by automated sequencing (data not shown). 
 The FDX1 gene (OMIM 103260) encodes an 
iron-sulfur protein, ferredoxin, also referred to as 
adrenodoxin. Ferredoxin serves as an electron transport 
intermediate for mitochondrial cytochrome P450. Elec-
trons are transferred from NADPH through a flavin-
containing protein (ferredoxin oxidoreductase) and ferre-
doxin to the terminal cytochrome P450 for 
oxidation/reduction reactions (Jefcoate et al. 1986). The 
gene contains 4 exons and 3 introns with a 540 bp coding 
region (Morel et al. 1988) and the results of our screening 
efforts excluded FDX1 as the disease-causing gene. 
 The SDHD gene (OMIM 602690) encodes a 
protein that belongs to the mitochondrial succinate dehy-
drogenase complex II (succinate-ubiquinone 
oxidoreductase) which represents an important enzyme 
complex in both the tricarboxylic acid cycle and the aero-
bic respiratory chains of mitochondria in eukaryotic cells 
and prokaryotic organisms (Hirawake et al. 1997). The 
gene contains 4 exons and 3 introns and was also ex-
cluded as the gene harboring mutations causing CP by 
automated sequencing of its entire coding region. While 
this work was in progress, different authors reported 
mutations in the SDHD gene underlying familial para-
gangliomas of the central nervous system (OMIM 
168000) (Baysal et al. 2000) and familial pheochromocy-
toma (OMIM 171300) (Astuti et al. 2001), thereby 
making it an even more unlikely candidate in a disorder 
of heme biosynthesis. 
 Although the original linkage report from Nor-
ton and coworkers actually excluded both the PBGD and 
PPO gene (Norton et al. 1993), we nevertheless decided 
to screen both genes by automated sequencing because 
the biochemical and enzymatic data published by McColl 
and colleagues indicated deficiencies of both PPOX and 
PBGD (McColl et al. 1985). 
 In accordance with the report of Norton and 
colleagues, sequencing analysis of the coding regions of 
the PPOX gene and its promoter region revealed no muta-
tion.  
 Surprisingly, however, in exon 9 of the PBGD 
gene we detected a sequence variation in four of the five 
individuals classified as being affected by the disease. 
The mutation consisted of a C-to-T transition in exon 9 of 
the PBGD gene, resulting in the change of an arginine 
residue to a premature termination codon, designated 
R149X. This mutation most likely will lead to distur-
bance of protein function by nonsense mediated 
messenger RNA decay of the mutated transcript (Hentze 
and Kulozik 1999). R149X was the only sequence variant 
detected in the CP family and was not found in 200 
chromosomes from healthy unrelated Caucasian control 
individuals.  
 Mutation R149X has already been previously 
described by Kauppinen and colleagues in the Finnish 
population (Kauppinen et al. 1995). The sequence varia-
tion occurs at a putatively hypermutable CpG 
dinucleotide leading to the substitution of arginine 
(CGA) by a premature termination codon (TGA). CpG 
dinucleotides were shown to represent hotspots for muta-
tions in vertebrate genomes (Cooper and Krawczak 
1990), and 35 % of all single basepair substitutions caus-
ing human genetic diseases were found to occur within 
CpG dinucleotide motifs (Copper and Youssoufian 
1988). In further support of the notion that codon 149 
apparently represents a hotspot for the occurrence of 
mutations within the PBGD gene two other sequence 
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variations at the same amino acid position have been 
previously reported, designated R149Q and R149L, re-
spectively (Delfau et al. 1991, Gu et al. 1994). 
 Of note, only four of the five individuals from 
the original CP family who were classified as suffering 
from the disease on the basis of previous biochemical and 
enzymatic studies indeed carried the disease causing 
mutation R149X, thereby possibly suggesting that the 
original classification into affected and non-affected 
individuals in the publications from McColl, Qadiri, 
Norton, and colleagues might have already been some-
what imprecise [McColl et al. 1985, Qadiri et al. 1986, 
Norton et al. 1993). This could also explain why the 
linkage data from Norton et al. erroneously indicated a 
novel chromosomal locus for CP and why the PBGD 
gene locus was excluded on the basis of recombination 
events in certain family members (Norton et al. 1993), if 
these family members revealing the crucial recombina-
tion events were perhaps wrongly classified prior to 
linkage.           
 Our data demonstrate that the individuals from 
the CP family studied herein do not suffer from a novel 
type of porphyria, but rather from a variant of AIP. It still 
remains elusive why some family members revealed the 
characteristic porphyrin excretion patterns of VP and 
reduced enzymatic activities of PPOX, likewise indica-
tive of VP. 
Interestingly, however, other authors have previously 
pointed out that biochemical analyses and even the meas-
urement of enzymatic activities in fibroblasts or 
lymphocytes are somewhat imprecise, since a certain 
overlap between the values measured in patients, clini-
cally unaffected mutation carriers (so called “silent” 
carriers), and normal control individuals can be found. 
Thus, the results of biochemical and even enzymatic 
studies in the porphyrias are not always conclusive, 
sometimes making an accurate diagnosis of the respective 
type of porphyria impossible (Da Silva et al. 1995, 
Grandchamp et al. 1996). In support of this notion, sev-
eral authors have previously reported that a coexistent 
decrease in PBGD activity can be frequently detected in 
patients suffering from VP who usually exhibit a catalytic 
deficiency of PPOX solely (Meissner et al. 1986, Doss et 
al. 1996, Weinlich et al. 2001). Still, in none of these 
individuals the existence of a dual porphyria could be 
confirmed on the genetic level. Even in a family who 
revealed a concomitant decrease in PBGD activity being 
as high as 50 % of the normal range no underlying muta-
tion in the PBGD gene was detected and, furthermore, 
this catalytic deficiency apparently had no clinical conse-
quences (Weinlich et al. 2001). In light of these reports, it 
seems admissible to speculate that the accompanying 
decrease in PPOX activity observed in some members the 
CP family can most likely be attributed to a phenomenon 
secondary to the disease causing genetic defect in the 
PBGD gene and, thus, has no consequences on the clini-
cal course of the disease.  
 The results of our studies in the CP family indi-
cate that CP is neither a dual porphyria, nor a separate 
type of porphyria but rather a variant of AIP. Our data 
also largely exclude the possibility that a hitherto un-
known gene is involved in the pathogenesis of the 
porphyrias. We further suggest that, whenever possible, 
all so-called double porphyrias should be confirmed on 
the genetic level first to prove the hypothesis of their 
existence.  
 
Acknowledgement  
This study was supported by grants from the “Interdisci-
plinary Center for Clinical Research in Biomaterials and 
Tissue-Material-Interaction in Implants” (BMBF project 
No. 01 KS 9503/9) to JF. PPG was supported by grant 
No. A/99/02925 from the Deutscher Akademischer 
Austauschdienst (DAAD). JF was supported by grant No. 
01 KX 9820/F from the Bundesministerium für Bildung 
und Forschung (BMBF).   
 
References 
 
ASTUTI D, DOUGLAS F, LENNARD TWJ, ALIGIANIS IA, WOODWARD ER, EVANS DGR, ENG C, LATIF F, 
MAHER ER: Germline SDHD mutation in familial phaeochromocytoma. Lancet 357: 1811-1182, 2001. 
BAYSAL BE, FERRELL RE, WILLETT-BROZICK JE, LAWRENCE EC, MYSSIOREK D, BOSCH A, VAN DER 
MAY A, TASCHNER PEM, RUBINSTEIN WS, MYERS EN, RICHARD III CW, CORNELISSE CJ,  
DEVILEE P, DEVLINB: Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. 
Science 287: 848-851, 2000. 
COOPER DN, YOUSSOUFIAN H: The CpG dinucleotide and human genetic disease. Hum Genet 78: 151-155, 1988. 
2006  Chester  Porphyria   S143  
   
COOPER DN, KRAWCZAK M: The mutational spectrum of single base-pair substitutions causing human genetic 
disease: patterns and predictions. Hum Genet 85: 55-74, 1990. 
CRIMLISK HL: The little imitator - porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 62: 319-
328, 1997. 
DA SILVA V, SIMONIN I, DEYBACH JC, PUY H, NORDMANN Y: Variegate porphyria: diagnostic value of 
fluorometric scanning of plasma porphyrins. Clin Chim Acta 238: 163-168, 1995. 
DAY RS, EALES L, MEISSNER D. Coexistent variegate porphyria and porphyria cutanea tarda. N Engl J Med 307: 
36-41, 1982. 
DELFAU MH, PICAT C, DE ROOIJ F, VOORTMAN G, DEYBACH JC, NORDMANN Y, GRANDCHAMP B: Mo-
lecular heterogeneity of acute intermittent porphyria: identification of four additional mutations resulting in the 
CRIM-negative subtype of the disease. Am J Hum Genet 49: 421-428, 1991. 
DOSS M: New dual form of porphyria. Lancet 1: 945-946, 1988. 
DOSS MO: New form of dual porphyria: coexistent acute intermittent porphyria and porphyria cutanea tarda. Eur J Clin 
Invest 19: 20-25, 1989a. 
DOSS MO: Dual porphyria in double heterozygotes with porphobilinogen deaminase and uroporphyrinogen decarboxy-
lase deficiencies. Clin Genet 35: 146-151, 1989b. 
DOSS MO, GROSS U, HONCAMP M, JACOB K. Variegate porphyria in Germany: A 25-year clinical, diagnostic, 
biochemical and therapeutic study. Hepatology 23: 285H, 1996. 
DOSS MO, GROSS U, PUY H, DOSS M, KUHNEL A, JACOB K, DEYBACH JC, NORDMANN Y. Coexistence of 
hereditary coproporphyria and porphyria cutanea tarda: a new form of dual porphyria. Med Klin 97: 1-5, 2002. 
ELDER GH. Update on enzyme and molecular defects in porphyria. Photodermatol Photoimmunol Photomed 14: 66-
69, 1998. 
FRANK J, AITA VM, AHMAD W, LAM H, WOLFF C, CHRISTIANO AM: Identification of a founder mutation in 
the protoporphyrinogen oxidase gene in variegate porphyria patients from Chile. Hum Hered 51: 160-168, 
2001. 
FRANK J, CHRISTIANO AM: The genetic bases of the porphyries. Skin Pharmacol Appl Skin Physiol 11: 297-309, 
1998. 
FRANK J, CSERHALMI-FRIEDMAN PB, AHMAD W, PANTELEYEV AA, AITA VM, CHRISTIANO AM. Char-
acterization of the desmosomal cadherin gene family: genomic organization of two desmoglein genes on 
human chromosome 18q12. Exp Dermatol 10: 90-94, 2001. 
FREESEMANN AG, HOFWEBER K, DOSS MO. Coexistence of deficiencies of uroporphyrinogen III synthase and 
decarboxylase in a patient with congenital erythropoietic porphyria and in his family. Eur J Clin Chem Clin 
Biochem 35: 35-39, 1997. 
GRANDCHAMP B, PUY H, LAMORIL J, DEYBACH JC, NORDMANN Y: Review: molecular pathogenesis of he-
patic acute porphyries. Gastroenterol Hepatol 11: 1046-1052, 1996. 
GREGOR A, KOSTRZEWSKA E, TARCZYNSKA-NOSAL S, STACHURSKA H: Coexistence of hereditary copro-
porphyria with acute intermittent porphyria. Ann Med 26: 125-127, 1994. 
GROENEWALD JZ, LIEBENBERG J, GROENEWALD IM, WARNICH L. Linkage disequilibrium analysis in a 
recently founded population: evaluation of the variegate porphyria founder in South African Afrikaners. Am J 
Hum Genet 62: 1254-1258, 1998. 
GU XF, DE ROOIJ F, VOORTMAN G, TE VELDE K, DEYBACH JC, NORDMANN Y, GRANDCHAMP B: Detec-
tion of eleven mutations causing acute intermittent porphyria using denaturing gradient gel electrophoresis. 
Hum Genet 93: 47-52, 1994. 
HENTZE MW, KULOZIK AE: A perfect message: RNA surveillance and nonsense-mediated decay. Cell 96: 307-310, 
1999. 
HIRAWAKE H, TANIWAKI M, TAMURA A, KOJIMA S, KITA K: Cytochrome b in human complex II (succinate-
ubiquinone oxidoreductase): cDNA cloning of the components in liver mitochondria and chromosome assign-
ment of the genes for the large (SDHC) and small (SDHD) subunits to 1q21 and 11q23. Cytogenet Cell Genet 
79: 132-138, 1997. 
S144   Poblete-Gutiérrez et al.  Vol. 55 
 
 
JEFCOATE CR, MCNAMARA BC, DIBARTOLOMEIS MJ: Control of steroid synthesis in adrenal fasciculata cells. 
Endocr Res 12: 314-350, 1986. 
KAUPPINEN R, MUSTAJOKI S, PIHLAJA H, PELTONEN L, MUSTAJOKI P: Acute intermittent porphyria in 
Finland: 19 mutations in the porphobilinogen deaminase gene. Hum Mol Genet 4: 215-222, 1995. 
KAUPPINEN R: Porphyrias: Lancet 365: 241-252, 2005. 
LEVINE J, JOHNSON WT, TSCHUDY DT: The co-existence of two types of porphyria in one family. Arch Dermatol 
114: 613-614, 1978.  
LIP GYH, MCCOLL KEL, MOORE MR: The acute porphyries. Br J Clin Pract 47: 38-43, 1993. 
MCCOLL KEL, THOMPSON GG, MOORE MR, GOLDBERG A. Chester porphyria: biochemical studies of a new 
form of acute porphyria. Lancet 2: 297-299, 1985. 
MEISSNER PN, DAY RS, MOORE MR, DISLER PB, HARLEY E. Protoporphyrinogen oxidase and porphobilinogen 
deaminase in variegate porphyria. Eur J Clin Invest 16: 257-261, 1986. 
MOREL Y, PICADO-LEONARD J, WU DA, CHANG CY, MOHANDAS TK, CHUNG BC, MILLER WL: Assign-
ment of the functional gene for human adrenodoxin to chromosome 11q13-qter and of adrenodoxin 
pseudogenes to chromosome 20cen-q13.1. Am J Hum Genet 43: 52-59, 1998. 
NORDMANN Y, AMRAM D, DEYBACH JC, PHUNG LN, LESBROS D: Coexistent hereditary coproporphyria and 
congenital erythropoietic porphyria (Gunther disease). J Inherit Metab Dis 13: 687-691, 1990. 
NORTON B, LANYON WG, MOORE MR, PORTEOUS M, YOUNGS GR, CONNOR JM. Evidence for involvement 
of a second genetic locus on chromosome 11q in porphyrin metabolism. Hum Genet 91: 576-578, 1993. 
QADIRI MR, CHURCH SE, MCCOLL KE, MOORE MR, YOUNGS GR. Chester porphyria: a clinical study of a new 
form of acute porphyria. Br Med J (Clin Res Ed) 292: 455-459, 1986. 
SAMBROOK J, EF FRITSCH EF, T MANIATIS (eds), Molecular cloning: A laboratory manual. Cold Spring Harbor, 
New York, Cold Spring Harbor Laboratory Press. 
SIEG I, BHUTANI LK, DOSS MO: Dual porphyria of coexisting variegata and cutanea tarda. Eur J Clin Chem Clin 
Biochem 33: 405-410, 1995. 
STURROCK ED, MEISSNER PN, MAEDER DL, KIRSCH RE: Uroporphyrinogen decarboxylase and protoporphy-
rinogen oxidase in dual porphyria. S Afr Med J 76: 405-408, 1989. 
WATSON CJ, CARDINAL RA, BOSSENMAIER I, PETRYKA ZJ: Porphyria variegata and porphyria cutanea tarda in 
siblings: chemical and genetic aspects. Proc Natl Acad Sci USA 72: 5126-5129, 1975. 
WEINLICH G, DOSS MO, SEPP N, FRITSCH P: Variegate porphyria with coexistent decrease in porphobilinogen 
deaminase activity. Acta Derm Venereol 81: 356-359, 2001. 
 
 
Reprint requests 
Jorge Frank, Afdeling Dermatologie, Academisch Ziekenhuis Maastricht, P. Debyelaan 25, Postbus 5800, 6202 AZ 
Maastricht, The Netherlands. Phone: 0031-43-3875292. Fax: 0031-43-3877293. E-mail: jfra@sder.azm.nl 
